Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe Study Details page updated its revision label from v3.6.3 to v3.6.4, representing a small page patch rather than new or altered study information.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision tag was updated to v3.6.3, indicating a small publishing update to the page's version rather than changes to the study data or displayed content.SummaryDifference0.0%

- Check38 days agoChange DetectedThe study details page revision tag was updated from v3.6.0 to v3.6.2, signaling a small maintenance update to the page’s underlying system.SummaryDifference0.0%

- Check52 days agoChange DetectedThe study record now indicates it is not actively enrolling participants and adds new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study); the revision tag was updated to v3.6.0 and the Intervention/Treatment heading formatting was adjusted.SummaryDifference0.4%

- Check59 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, signaling a minor maintenance update to the page.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page received a minor version update (revision to a newer build). This appears to be software maintenance with no visible changes to the study details, eligibility criteria, or results.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.